Engitix raises €21.0M Series A round
8 January 2026· London, United Kingdom· health, biotech, oncology, fibrosis, drug_discovery, ai, b2b
To continue preclinical development across Engitix's proprietary ECM-targeted pipeline in solid tumors and fibrosis, and to further expand and apply its platform built on one of the largest proprietary ECM datasets in these diseases.
Investors
LeadNetherton Investments
About Engitix
Stage
Series A
Headquarters
London, United Kingdom
Founded
2016
Team Size
51–200
Sectors
healthbiotechoncologyfibrosisdrug_discoveryaib2b